Outlook Therapeutics named Greg DiPasquale chief commercial officer, marking a commercial leadership update at the vision-health drug developer. The move comes as the company outlines market plans for LYTENAVA, a key pipeline asset.
published
Outlook Therapeutics named Greg DiPasquale chief commercial officer, marking a commercial leadership update at the vision-health drug developer. The move comes as the company outlines market plans for LYTENAVA, a key pipeline asset.
Latest documented BWB result
$SECZ market result
Exit $SECZ with .95 profit per share - thanks to a nice after hours pop. Will re-enter tomorrow most likely
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.